KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Pembrolizumab showed a 44% pathological complete response rate in dMMR colon cancer patients, with a major pathological response in 57%. Minimal severe side effects were observed, with 8% experiencing ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

(RTTNews) - Merck & Co. Inc. (MRK) said Tuesday that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

On Friday, Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESAIY) (OTC:ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combination ...